TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1983112
Drug: nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine (300 mg h.s.)
Study: 1983112
Drug: famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (40 mg h.s.)
Study: 7016432
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of 15-methyl-PGF2 alpha methyl ester in a vaginal suppository
Study: 27866454
Drug: Pemetrexed continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed continuation maintenance therapy
Study: 24140442
Drug: Prolonged release
Normalized name: EYE DROPS, PROLONGED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release oxycodone-naloxone (5.0 mg oxycodone, 2.5 mg naloxone, twice per day, up-titrated to a maximum of 40 mg oxycodone, 20 mg naloxone, twice per day)
Study: 24140442
Drug: Prolonged release
Normalized name: EYE DROPS, PROLONGED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release oxycodone-naloxone (during open-label extension phase)
Study: 24140442
Drug: Prolonged release
Normalized name: EYE DROPS, PROLONGED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release oxycodone-naloxone
Study: 21873926
Drug: Corneal refractive
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal refractive therapy
Study: 19188184
Drug: p53 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 synthetic long peptide (p53-SLP) vaccine, administered twice
Study: 17595592
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with estradiol patches (50 microg/24 h) and oral medroxyprogesterone acetate (2.5 mg/d)
Study: 9672273
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day for 5 years
Study: 9672273
Drug: Tamoxifen among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen among women using hormone-replacement therapy
Study: 9672273
Drug: Placebo among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo among women using hormone-replacement therapy
Study: 8023775
Drug: L-propionylcarnitine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (15 mg/kg)
Study: 3076382
Drug: Total lymphoid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total lymphoid irradiation (TLI) (radiation dose, 20-30 Gy)
Study: 19271065
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (Group P)
Study: 19271065
Drug: Desflurane inhalation
Normalized name: Desflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane inhalation (Group D)
Study: 10867454
Drug: Simple closure
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple closure with postsurgery medical treatment (proton pump inhibitors for 1 month)
Study: 10867454
Drug: Vagotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagotomy and pyloroplasty with no additional medical treatment
Study: 9089001
Drug: Demotussol Hustensirup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demotussol Hustensirup (syrup)
Study: 9089001
Drug: Sinecod Sirup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinecod Sirup (syrup)
Study: 9089001
Drug: Demotussol Tabletten
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demotussol Tabletten (tablet)
Study: 9089001
Drug: Demotussol Hustentropfen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demotussol Hustentropfen (solution)
Study: 8404115
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention with daily use of a metered-dose inhaler with ipratropium bromide
Study: 8404115
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention with inhalation of placebo
Study: 2957569
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg/day for 6 months)
Study: 28306636
Drug: perindopril/indapamide/amlodipine 5/1.25/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/indapamide/amlodipine 5/1.25/5 mg
Study: 28306636
Drug: perindopril/indapamide/amlodipine 10/2.5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/indapamide/amlodipine 10/2.5/10 mg (up-titration)
Study: 28306636
Drug: perindopril/indapamide 5/1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/indapamide 5/1.25 mg
Study: 21504973
Drug: Muscadine grape
Normalized name: Muscadine Grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscadine grape seed supplementation (1300 mg daily)
Study: 15888038
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance regimen (no steroids at all)
Study: 15888038
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal regimen (steroids for the first 3 months)
Study: 27214389
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate treatment
Study: 27020837
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (FSS) effective dose (100-1600 µg)
Study: 15479896
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral prednisolone/day for three weeks
Study: 7530437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha fetoprotein and free beta human chorionic gonadotropin
Study: 2902114
Drug: Levocabastine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (0.5 mg/ml, one drop twice a day)
Study: 2902114
Drug: Screening test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening test (no medication)
Study: 25322606
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg) intravenous injection
Study: 20428741
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 ug)
Study: 18275768
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids and immunosuppressive drugs (cyclophosphamide)
Study: 2123115
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin
Study: 2123115
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg leuprorelin
Study: 30652777
Drug: Brief Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Group Intervention (BGI) with four group sessions, weekly meetings
Study: 27679533
Drug: FAST‐MAG clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAST‐MAG clinical trial (Field Administration of Stroke Therapy‐Magnesium)
Study: 24523488
Drug: Dose-dilution protocol
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dilution protocol
Study: 14564193
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of peritoneal small molecule clearance delivered by chronic ambulatory peritoneal dialysis
Study: 30104718
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and autologous stem cell transplantation
Study: 9058342
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg itraconazole (one-day monthly prophylaxis for six months)
Study: 8375881
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (40 mg elemental iron/day) for six months
Study: 3091138
Drug: Oestrogen (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen (160 mg polyestradiol phosphate intramuscularly every month for the first three months, then 80 mg monthly, plus ethinyloestradiol 1 mg by mouth daily for the first two weeks, then 150 micrograms daily)
Study: 25066223
Drug: MCT +
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT + treatment as usual (TAU)
Study: 18540734
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for pain (P)
Study: 18540734
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation and emotion regulation therapy (M)
Study: 15846228
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized estradiol (E2) 1 mg/day
Study: 15846228
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg/day + MPA 10 mg/day
Study: 15846228
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (P4) 300 mg/day
Study: 15846228
Drug: Norethindrone (NET)
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone (NET) 1 mg/day
Study: 15846228
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (1000 mg of calcium and 400 IU of vitamin D/day)
Study: 7752832
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) therapy
Study: 7752832
Drug: Anthracyclines (ANT)
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracyclines (ANT) without CoQ therapy
Study: 3281412
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg daily for the first 3 months
Study: 3281412
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for the first 3 months
Study: 3281412
Drug: Metoprolol (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (early treatment, ≤ 8 hours after onset of pain)
Study: 3281412
Drug: Placebo (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (early treatment, ≤ 8 hours after onset of pain)
Study: 3281412
Drug: Metoprolol (late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (late treatment, > 8 hours after onset of pain)
Study: 3281412
Drug: Placebo (late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (late treatment, > 8 hours after onset of pain)
Study: 20209976
Drug: Medication (Yueyueshu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Yueyueshu Granules)
Study: 17549294
Drug: Rivaroxaban (5-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5-60 mg, oral, twice-daily)
Study: 17549294
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily before THR, 30 mg bid after TKR)
Study: 17549294
Drug: Rivaroxaban (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5-20 mg)
Study: 11477494
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (8 week supervised program, aerobic exercise at 75% VO(2) peak, 45 min, twice a week; intermittent exercise once a week)
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) with zidovudine (AZT)
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered sequentially (2 hours before ganciclovir)
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered simultaneously
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) with probenecid
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) administered 2 hours after didanosine (ddI)
Study: 9495222
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours) with no coadministration
Study: 2902319
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg/m2 by mouth, nightly for 6 months)
Study: 29939961
Drug: Interoceptive Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interoceptive Exposure (IE) therapy
Study: 28743198
Drug: Relaxation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation Therapy (RT)
Study: 28614188
Drug: Sham opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham opioid solution (NaCl) with verbal instruction that it reduces pain and improves physical capacity
Study: 28614188
Drug: Inactive solution
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive solution (NaCl) presented as an effective treatment
Study: 23347341
Drug: AndroGel 1%
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel 1% 5 g, 7.5 g, or 10 g once daily for 6 months (Study 1)
Study: 23347341
Drug: AndroGel 1%
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel 1% 7.5 g once daily titrated as needed (Study 2)
Study: 23347341
Drug: AndroGel 1%
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel 1% 5 g once daily (Study 3)
Study: 19296208
Drug: Nasal powder
Normalized name: NASAL POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal powder formulation
Study: 19296208
Drug: Commercial nasal
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial nasal liquid spray
Study: 9079231
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet
Study: 18031872
Drug: HBsAg with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks
Study: 18031872
Drug: lamivudine daily
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine daily alone
Study: 14727216
Drug: Indinavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (800 mg) and Ritonavir (100 mg) twice a day with Rifampin (300 mg every day for 4 days)
Study: 9629648
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential method based on the sequential conditional probability ratio test
Study: 9629648
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential method
Study: 8067842
Drug: Heparin-coated membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated membrane oxygenators (100 IU/kg heparin)
Study: 8067842
Drug: Noncoated control
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noncoated control membrane oxygenators (300 IU/kg heparin)
Study: 31489293
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 (weekly)
Study: 31489293
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 (3 weekly)
Study: 25908501
Drug: Therapeutic massage
Normalized name: All Body Powerful Therapeutic Massager
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic massage (effleurage, kneading, and trigger point therapy) for 10 minutes, four times per week for 4 weeks
Study: 16952489
Drug: Tariquidar (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (150 mg over 30 minutes)
Study: 8406149
Drug: Liquid fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid fibre (250 ml)
Study: 30021691
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of montelukast/levocetirizine 10/5 mg
Study: 30021691
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of montelukast and levocetirizine
Study: 27180088
Drug: Patient navigation
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient navigation plus medications
Study: 25223180
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (mainly by GC and cyclophosphamide)
Study: 8560598
Drug: R‐ORS (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐ORS (50 g/L)
Study: 1537131
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.7 g/day of eicosapentaenoic acid, 1.8 g/day of docosahexaenoic acid)
Study: 1537131
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of omega-3 fatty acids > 0.15 g/day
Study: 27622998
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (DT) with midodrine and rifaximin (n=400)
Study: 27622998
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (DT) only (n=200)
Study: 22632139
Drug: Telephone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based intervention consisting of four sessions of motivational interviewing (MI) and cognitive behavioural therapy (CBT)
Study: 19361872
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (40 mg administered three times daily)
Study: 2625616
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic (Phenyltrope)
Study: 857369
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (2 X 500 ml i.v.)
Study: 28592037
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii 500 mg twice a day for 21 days
Study: 26288285
Drug: APTPA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTPA (500 mg glucosamine hydrochloride and 500 mg chondroitin sulfate) + melaxen (3 mg melatonin 30-40 min before sleep)
Study: 26288285
Drug: APTPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTPA (1 tablet twice a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Study: 26288285
Drug: APTPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Study: 26288285
Drug: APTPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day)
Study: 26288285
Drug: APTPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) without melaxen
Study: 21396091
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal pessaries (100 mg) for 6 days
Study: 21396091
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no treatment, routine antenatal care)
Study: 18287162
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region
Study: 18287162
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment only (same dosage)
Study: 18287162
Drug: Healthy individuals
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy individuals without treatment (control group)
Study: 3512619
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 0.5 mg/kg/d
Study: 3512619
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 15 mg/kg/d
Study: 3512619
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 0.5 mg/kg/d and 15 mg/kg/d
Study: 27538952
Drug: Xinyue capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinyue capsules (1.8 g/day, three times daily for up to 24 weeks)
Study: 27538952
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (three times daily for up to 24 weeks)
Study: 25431770
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day essential amino acids (EAAs); n=19
Study: 17449306
Drug: Neramexane (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neramexane (40 mg p.o.)
Study: 17449306
Drug: Flupirtine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (100 mg)
Study: 15946202
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of nadroparin (2850 a‐Xa IU)
Study: 15946202
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of nadroparin (body-weight adjusted)
Study: 12891111
Drug: Self-administered WIQ
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered WIQ
Study: 12891111
Drug: Telephone-administered WIQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered WIQ